Glofitamab Treatment for DLBCL Shows Cost Savings Over Epcoritamab in US Healthcare
TL/DR –
Glofitamab and epcoritamab are approved treatments in the US for diffuse large B-cell lymphoma (DLBCL) after two or more prior therapies. A recent economic model estimated the per-patient total cost of care (TCC) for these two treatments and found glofitamab to have lower costs across all treatment durations and cycles. Despite higher costs related to adverse events and treatment administration for glofitamab, the overall lower treatment costs made it more cost-effective, offering greater budget predictability and cost savings at both the healthcare system and population levels.
Cost Analysis: Glofitamab versus Epcoritamab for Diffuse Large B-cell Lymphoma Treatment
The US healthcare system has approved fixed-treatment duration glofitamab and treat-to-progression epcoritamab for patients with diffuse large B-cell lymphoma (DLBCL) who have undergone at least two prior therapies. A new economic model has been created to estimate the per-patient total cost of care (TCC) of glofitamab against that of epcoritamab. The model is based on treatment costs derived from time-to-off-treatment (NCT03075696 for glofitamab) and progression-free survival (NCT03625037 for epcoritamab).
The model indicates potential per-patient cost savings with glofitamab over epcoritamab across cycles 1-3 (-$56,275), 6 months (-$37,982), 1 year (-$68,195), 5 years (-$223,692), 10 years (-$325,175) and even across a lifetime (-$503,075), all adjusted to 2023 US dollars. Despite glofitamab bearing higher costs for adverse event ($364) and treatment administration ($8,398) compared to epcoritamab, these are counterbalanced by the consistently lower treatment costs of glofitamab across all time horizons.
The findings suggest that glofitamab not only offers per-patient TCC savings versus epcoritamab at every cumulative cycle but also provides more budget predictability and cost savings at both healthcare system and population levels.
Keywords:
DLBCL, Glofitamab, bispecifics, cost analysis, epcoritamab, relapsed/refractory.
—
Read More Health & Wellness News ; US News